We work to map the microbiome and illuminate interactions foundational to the health of humanity.

Triple Impact Capital

Uncommon Denominator

Lions Capital

Cooke

DCVC

Kanvas Biosciences

Viewport Meta

IPhone / Mobile Compatible

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Analytics

Content Delivery Network

Global Site Tag

Google Analytics 4

PostalAddress Schema

Paul Theunissen

Ashlie Burkart

Jason Pontin

Matthew Cheng

CEO, Co-Founder

Hao Shi

Founder, CTO

Northeastern US Companies With Less Than $10M in Revenue (Top 10K)

East Coast Early Stage Companies

New Jersey Companies With Fewer Than 100 Employees (Top 10K)

East Coast Companies (Top 10K)

Our full-stack tech­nol­o­gy plat­form brings micro­bio­me drug dis­cov­ery into focus. Our spa­tial map­ping dis­cov­ery engine pro­vides stun­ning pic­tures of the inter­ac­tions and con­nec­tions between host and the micro­bio­me; an area of this vital sys­tem that we’ve nev­er been able to com­plete­ly under­stand before. Spa­tial biol­o­gy of the host-micro­bio­me inter­face pro­vides new oppor­tu­ni­ties for effec­tive ther­a­peu­tic inter­ven­tions, ulti­mate­ly enabling us to bet­ter treat patients.

Series A - Kanvas Biosciences

Seed Round - Kanvas Biosciences

Monmouth Junction

New Jersey

United States

North America

Kanvas Bio Unveils Clinical Data on the Gut Microbiome’s Impact on Anti-Tumoral Immunity at SITC

Kanvas Biosciences Secures Additional $12.5M in Funding

Kanvas Biosciences Secures Additional $12.5M to Advance Its Novel, Microbiome-Based Immuno-oncology Drug Candidates to IND Filing

Kanvas Biosciences Introduces New Drug Candidate in its Immuno-oncology Program

Kanvas Biosciences raises funding to advance live biotherapeutic products for cancer patients

This Startup Raised $12.5 Million To Find Bacteria To Help Fight Cancer

A technology platform for microbiome drug discovery, providing detailed images of host-microbiome interactions.

Develops live biotherapeutics aimed at modulating the microbiome for health and disease treatment.

A high-resolution imaging platform for identifying and characterizing microbial communities.

Anaerobic Co-culture Technology for large-scale manufacturing of microbial consortia.

Collaborations with biotechnology and pharmaceutical companies for microbiome understanding and drug candidate exploration.

A drug candidate targeting cancer immunotherapy potentiation, in development with MD Anderson Cancer Center.

Biolog is a company focused on microbiology and microbial identification.

Biolog

Rapid Micro Biosystems specializes in automated, rapid microbial detection technology.

Rapid Micro Biosystems

Pragma Bio is a biotechnology company focused on microbiome research and therapeutics.

Pragma Bio

Cyclica is a biotechnology company specializing in AI-augmented drug discovery, including microbiome-related research.

Cyclica

Relay Therapeutics is a biotechnology company leveraging computational approaches for drug discovery, including microbiome-related research.

Relay Therapeutics

METiS Therapeutics is a biotechnology company focused on microbiome-based drug discovery and development.

METiS Therapeutics

Cellarity is a biotechnology company specializing in cellular therapeutics, including microbiome-related research.

Cellarity

Finch Therapeutics is a biotechnology company focused on developing microbiome-based therapeutics for various diseases.

Finch Therapeutics

Kaleido Biosciences is a biotechnology company specializing in the development of novel microbiome-based medicines.

Kaleido Biosciences

Kanvas Biosciences is a biotechnology company focused on leveraging spatial biology to understand and map the interactions between the human host and the microbiome. Their goal is to facilitate the discovery of new therapeutics for various diseases by providing a comprehensive understanding of the host-microbiome interface.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Jul 2, 2024 12:58 PM	15ad8ea7
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jul 2, 2024 1:11 PM	d90583ed
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:09 AM	27013742
crunchbase profile	general	Nov 25, 2024 9:17 AM	ddc06a1b
li profile	general	Jul 2, 2024 12:58 PM	0c6cd811
translate crunchbase fundingrounds	general	Nov 25, 2024 2:06 PM	f4e6403a
peers	general
news basic	general	Jul 2, 2024 12:58 PM	fa01011c
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:KANVASBIO

Kanvas Biosciences